Approval of Sofdra marks the first chemical entity to be approved by the FDA to treat primary axillary hyperhidrosis.
Related Posts
Pharma Pulse 7/3/24: What to Know About New and Future ALZ Drugs, Bridging the Gap Between Innovation and Implementation & more
Pharma Pulse 7/5/24: The Impact of FDA's Diversity Action Plan, Apple Poised to Get OpenAI Board Observer Role & more